The in-vitro activity of grepafloxacin was compared with that of other antimicrobials against respiratory tract pathogens collected from 15 UK laboratories over the winter of 1995-96. Penicillin-resistant Streptococcus pneumoniae was not encountered, but macrolide resistance was seen in ~10% of strains. Grepafloxacin (MIC 90 0.25 mg/L) was four-to eight-fold more active than ciprofloxacin. Twelve percent of Haemophilus influenzae were -lactamase producers, macrolides were relatively inactive yet fluoroquinolones were highly active. Moraxella catarrhalis were highly susceptible to fluoroquinolones and macrolides.
Introduction
Grepafloxacin is a new monofluorinated fluoroquinolone with a novel methyl substituent at position 7. It has been shown to have high activity against a wide range of Gramnegative and Gram-positive bacteria, including respiratory pathogens. [1] [2] [3] [4] In this study the in-vitro activity of grepafloxacin was compared with that of seven other antimicrobial agents in common clinical use, against respiratory tract pathogens isolated in the UK.
Materials and methods

Strains
In the winter of 1995-96, sequential strains of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis were collected from 15 diagnostic laboratories in the UK from known cases of lower respiratory tract infections and sent to the City Hospital, Dudley Road, Birmingham. The strain identity was checked by routine methods and the susceptibilities performed on one occasion including control strains of known MICs. In addition strains with known mechanisms of resistance to -lactams and fluoroquinolones were included.
Susceptibility testing
The susceptibilities of the strains were studied employing a standard agar plate dilution method. The antibiotics were obtained from their respective suppliers. The organisms were grown on Iso-Sensitest agar (Oxoid, Basingstoke, UK) with 5% whole horse blood (for S. pneumoniae and M. catarrhalis) or chocolate agar (H. influenzae). Suspensions were prepared with a viable count of about 10 8 cfu/mL. -Lactamase production in H. influenzae and M. catarrhalis was determined using nitrocefin discs.
One microlitre of a 1:100 dilution of the suspension was transferred to the surface of the antibiotic-containing agar using a multi-point inoculator (Denley-Tech, Billingshurst, UK). The final inoculum size was 10 4 cfu. The medium used for the agar dilution procedure was Iso-Sensitest agar (pH 7.2, Oxoid) supplemented with 5% whole horse blood for S. pneumoniae and M. catarrhalis or 20 mg/L NAD (Sigma, Poole, Dorset, UK) for H. influenzae.
All plates were incubated in air at 35-37°C for 24 h (for streptococci and H. influenzae the air contained 4-6% carbon dioxide). The MIC of the antibiotic was defined as that concentration at which no more than two or three colonies were detected after the 24 h incubation. Table I shows the susceptibilities of the strains collected in the 1995-96 survey. None of the 63 strains of S. pneumoniae had a penicillin MIC of 0.1 mg/L, reflecting the low incidence of penicillin-resistance in the UK. Grepafloxacin was four-to eight-fold more active than ciprofloxacin. No quinolone-resistant strains were encountered. All the penicillins studied showed high activity, being approximately ten-fold more active than the cephalosporins. Although clarithromycin was active against the majority of strains, six of the 63 strains were inhibited by 16 mg/L. Approximately 12% of H. influenzae (nine of 76 strains) were -lactamase producers. The fluoroquinolones were equally active against both the -lactamase producers and non-producers; a similar observation was noted for the cephalosporins, although some strains which were less susceptible to cefaclor (e.g. MIC 16 and 32 mg/L) were highly susceptible to cefixime (MIC 0.06 mg/L). Clarithromycin demonstrated poor activity, having MICs of 2 mg/L against all strains.
Results
Eighty-four per cent of M. catarrhalis strains werelactamase producers. Grepafloxacin was the most active compound studied, being twice as active as ciprofloxacin.
In Table II the activities of grepafloxacin and ciprofloxacin against eight clinical strains and two defined fluoroquinolone-resistant (ciprofloxacin MIC 4 mg/L) mutants of S. pneumoniae are shown.
All the clinical strains were more susceptible to grepafloxacin than to ciprofloxacin; two strains demonstrated a 16-fold difference but four strains only showed a two-fold difference in susceptibility. The activity of grepafloxacin against the parC mutant was 1 mg/L and the additional gyrA mutation increased the MIC further to 32 mg/L. Table III shows the activity of five antimicrobials against four strains of known penicillin-resistant S. pneumoniae. The poor activity of cefixime was apparent as was the variable susceptibility to clarithromycin. Grepafloxacin was the most active agent studied. One of the intermediately penicillin-resistant strains was resistant to both fluoroquinolones and clarithromycin.
28
Discussion
This department first studied grepafloxacin activity in 1992 1 and the susceptibility of respiratory pathogens to this agent and ciprofloxacin does not appear to have changed significantly since then. Ninety per cent of the recent isolates of S. pneumoniae were inhibited by 0.5 mg/L of grepafloxacin and 2 mg/L of ciprofloxacin compared with 0.25 and 2 mg/L, respectively, in 1995-96. The other respiratory pathogens studied remain susceptible to fluoroquinolones.
Since that time, however, susceptibilities to other agents have altered. S. pneumoniae has demonstrated increasing resistance to -lactam antibiotics, 5 although this remains uncommon in the UK at 5% 6 but with local variation. 7 We encountered no such strains in our small survey. Macrolide resistance in S. pneumoniae is increasing; Goldstein & Acar, as part of the Alexander Project, 6 demonstrated an increase in the MIC 90 of clarithromycin from 0.12 mg/L in 1992 to 32 mg/L in 1993 in one location. They make the comment that 30% of penicillin-resistant S. pneumoniae are resistant to macrolides. The therapeutic options are therefore diminishing and the use of the fluoroquinolones, especially those with enhanced Gram-positive activity such as grepafloxacin, is being re-assessed.
This study noted that 12% of H. influenzae producedlactamase, a lower percentage than found in other countries 5 but an increasing problem. -Lactamase-negative ampicillin-resistant strains, defined by a breakpoint of 4 mg/L, were rare in this study (only one out of 154 isolates). The new oral cephalosporins showed variable activity with cefixime being very active while cefaclor was poorer. Macrolides are usually considered, at best, to have poor activity, as exemplified by the results with clarithromycin. The fluoroquinolones were the most active compounds encountered.
M. catarrhalis is now largely resistant to penicillins but macrolides and fluoroquinolones remain highly active as is shown in this study.
The increased use of fluoroquinolones in the therapy of respiratory tract infections is not without potential problems. Rarely, resistant mutants of various respiratory pathogens have been described in the laboratory and clinically, 8 and as shown in this study, cross-resistance between fluoroquinolones is a common observation, although variable in degree.
The treatment of respiratory tract infections is not only the commonest reason for antibiotic prescribing but also a rapidly changing scene. The new fluoroquinolones such as grepafloxacin, with enhanced activity against respiratory pathogens may have an important role. 
